Follow
Bert O'Neil
Bert O'Neil
Verified email at iu.edu
Title
Cited by
Cited by
Year
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ...
Nature 575 (7781), 217-223, 2019
16932019
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
8212017
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in …
HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'Neil, ...
Journal of clinical oncology 23 (23), 5305-5313, 2005
8042005
Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164
DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ...
Journal of Clinical Oncology 38 (1), 11, 2020
7822020
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 …
PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ...
Journal of Clinical Oncology 37 (4), 318-327, 2019
7462019
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ...
Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014
6442014
The proteasome as a target for cancer therapy
PM Voorhees, EC Dees, B O’Neil, RZ Orlowski
Clinical cancer research 9 (17), 6316-6325, 2003
5862003
Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB …
AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ...
Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016
4852016
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ...
Journal of clinical oncology 23 (11), 2502-2512, 2005
4812005
Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial
JS Frenel, C Le Tourneau, B O’Neil, PA Ott, SA Piha-Paul, C Gomez-Roca, ...
Journal of Clinical Oncology 35 (36), 4035-4041, 2017
4412017
Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting
MB Thomas, D Jaffe, MM Choti, J Belghiti, S Curley, Y Fong, G Gores, ...
Journal of clinical oncology 28 (25), 3994, 2010
4332010
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
BH O'Neil, R Allen, DR Spigel, TE Stinchcombe, DT Moore, JD Berlin, ...
Journal of Clinical Oncology 25 (24), 3644-3648, 2007
3622007
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers
T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ...
Journal of clinical oncology 29 (17), 2357, 2011
3502011
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ...
PloS one 12 (12), e0189848, 2017
2542017
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid …
M Fakih, B O'Neil, TJ Price, GS Falchook, J Desai, J Kuo, R Govindan, ...
Journal of Clinical Oncology 37 (15_suppl), 3003-3003, 2019
1772019
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma
BH O'Neil, LW Goff, JSW Kauh, JR Strosberg, TS Bekaii-Saab, R Lee, ...
Journal of Clinical Oncology 29 (17), 2350, 2011
1742011
Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study
J Strosberg, N Mizuno, T Doi, E Grande, JP Delord, R Shapira-Frommer, ...
Clinical cancer research 26 (9), 2124-2130, 2020
1652020
A multidisciplinary approach to pancreas cancer in 2016: a review
EL Fogel, S Shahda, K Sandrasegaran, J DeWitt, JJ Easler, DM Agarwal, ...
Official journal of the American College of Gastroenterology| ACG 112 (4 …, 2017
1412017
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
T Bekaii-Saab, J Markowitz, N Prescott, W Sadee, N Heerema, L Wei, ...
Clinical Cancer Research 15 (18), 5895-5901, 2009
1362009
First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors
SA Piha-Paul, JC Sachdev, M Barve, P LoRusso, R Szmulewitz, SP Patel, ...
Clinical Cancer Research 25 (21), 6309-6319, 2019
1312019
The system can't perform the operation now. Try again later.
Articles 1–20